** Shares of biotech Jasper Therapeutics JSPR.O rise 43% to $1.12 in extended trading

** JSPR says it has completed its acquisition of privately held Kira Pharmaceuticals in an all-stock transaction

** The combined company will focus on developing treatments for immune-related diseases, including Kira's lead drug candidate KP-104 for a rare blood disorder and kidney diseases, Jasper's briquilimab program and Kira's preclinical KP-701 antibody program

** Existing Jasper shareholders will receive a non-transferable CVR tied to potential $30 million aggregate payments if Jasper obtains and monetizes a priority review voucher for briquilimab by December 31, 2028

** Kira licensed two of its drug candidates KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront plus potential development and sales milestones, Jasper says

** As of last close, JSPR stock down 57% YTD